Hereditary spherocytosis epidemiology and demographics
|
Hereditary spherocytosis Microchapters |
|
Differentiating Hereditary spherocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hereditary spherocytosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hereditary spherocytosis epidemiology and demographics |
|
FDA on Hereditary spherocytosis epidemiology and demographics |
|
CDC on Hereditary spherocytosis epidemiology and demographics |
|
Hereditary spherocytosis epidemiology and demographics in the news |
|
Blogs on Hereditary spherocytosis epidemiology and demographics |
|
Risk calculators and risk factors for Hereditary spherocytosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
HS is seen in all populations but appears to be especially common in people of northern European ancestry.
Epidemiology and Demographics
- Hereditary spherocytosis is reported worldwide in all racial and ethnic groups.[1]
- It is the most common inherited anemia in the northern European ancestry and north america.[2]
- The reported incidence of hereditary spherocytosis is 1 in 2000 births.[3]
- It is less commonly seen in african american and southeast asian people.[4]
Incidence
- In the United States, the incidence of the disorder is approximately one case in 5000 people.
- Given that approximately 25% of all HS is autosomal recessive, calculations indicate that 1.4% of the US population might be silent carriers of HS.
Prevalence
- In northern European, HS affects as many as 1 in 2000 to 1 in 5000 (prevalence, approximately 0.02 to 0.05 percent) [6,7,62,75].
- The frequency is thought to be lower in individuals from other parts of the world such as Africa and Southeast Asia, although comprehensive population survey data are unavailable.
Age
- HS can present at any age and with any severity, with case reports describing a range of presentations, from hydrops fetalis in utero through diagnosis in the ninth decade of life.[5][6]
- HS is most often diagnosed in childhood or early adulthood.
- Children diagnosed early in life usually have a severe form of HS that results in their early presentation. Jaundice is likely to be most prominent in newborns. The magnitude of hyperbilirubinemia may be such that exchange transfusion is required. Approximately 30-50% of adults with HS had a history of jaundice during the first week of life. Recognition of HS as a potential cause of neonatal anemia and hyperbilirubinemia and institution of prompt treatment may reduce the risk of bilirubin-induced neurologic dysfunction in these patients.[7]
Race
- Hereditary spherocytosis occurs in all racial and ethnic groups but is more common in northern Europeans,
Gender
- There is no significant data from US related to gender difference. In 2011, the number of cases was 114 reported from CBM(China Biology Medicine) database, the male: female ratio was 1.04:1.[8]
- In 2011, overall literature reported prevalence of hereditary spherocytosis in China was estimated to be: 1.27 cases per 100,000 people in males and 1.49 cases per 100,000 people in females
Region
- Hereditary spherocytosis occurs in 1 in 5,000 individuals of Northern European ancestry. This condition is the most common cause of inherited anemia in that population. The prevalence of hereditary spherocytosis in people of other ethnic backgrounds is unknown, but it is much less common.
Developed Countries
There is no particular relation of FA with developed countries.
Developing Countries
There is no particular relation of FA with developing countries.
References
- ↑ Silverio Perrotta, Patrick G. Gallagher & Narla Mohandas (2008). "Hereditary spherocytosis". Lancet (London, England). 372 (9647): 1411–1426. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465. Unknown parameter
|month=ignored (help) - ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help) - ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help) - ↑ Perrotta, Silverio; Gallagher, Patrick G; Mohandas, Narla (2008). "Hereditary spherocytosis". The Lancet. 372 (9647): 1411–1426. doi:10.1016/S0140-6736(08)61588-3. ISSN 0140-6736.
- ↑ Perrotta S, Gallagher PG, Mohandas N (2008). "Hereditary spherocytosis". Lancet. 372 (9647): 1411–26. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465.
- ↑ Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA (1991). "Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis". Blood. 78 (11): 3043–51. PMID 1954389.
- ↑ Christensen RD, Yaish HM, Gallagher PG (2015). "A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates". Pediatrics. 135 (6): 1107–14. doi:10.1542/peds.2014-3516. PMC 4444801. PMID 26009624.
- ↑ Wang C, Cui Y, Li Y, Liu X, Han J (2015). "A systematic review of hereditary spherocytosis reported in Chinese biomedical journals from 1978 to 2013 and estimation of the prevalence of the disease using a disease model". Intractable Rare Dis Res. 4 (2): 76–81. doi:10.5582/irdr.2015.01002. PMC 4428190. PMID 25984425.